Effects of amphetamine on subcellular distribution of dopamine and DOPAC

Synapse

Volumn 66, Issue 7, 2012, Pages 592-607

  Wallace, Lane J ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Computational model; DAT; MAO; Striatum; VMAT

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; AMINE OXIDASE (FLAVIN CONTAINING); AMPHETAMINE; DOPAMINE; DOPAMINE TRANSPORTER; VESICULAR MONOAMINE TRANSPORTER;

ARTICLE; CELL MEMBRANE; CELL VACUOLE; CELLULAR DISTRIBUTION; COMPUTER SIMULATION; CYTOSOL; DIFFUSION; DRUG EFFECT; ENZYME INHIBITION; PRIORITY JOURNAL;

3,4-DIHYDROXYPHENYLACETIC ACID; AMPHETAMINES; COMPUTER SIMULATION; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; INTRACELLULAR SPACE; MODELS, NEUROLOGICAL; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84860884534     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.21546     Document Type: Article

References (132)

1. Afanas'ev, II, Anderzhanova EA, Kudrin VS, Rayevsky KS. 2001. Effects of amphetamine and sydnocarb on dopamine release and free radical generation n rat striatum. Pharmacol Biochem Behav 69: 653-658.
2. Anden NE, Fuxe K, Hamberger B, Hokfelt T. 1966. A quantitative study on the nigro-neostriatal dopamine neuron system in the rat. Acta Physiol Scan 67: 306-312.
3. Badiani A, Camp DM, Robinson TE. 1997. Enduring enhancement of amphetamine sensitization by drug-associated environmental stimuli. J Pharmacol Exp Ther 282: 787-794.
4. Badiani A, Oates MM, Day HEW, Watson SJ, Akil H, Robinson TE. 1998. Amphetamine-induced behavior, dopamine release, and c-fos mRNA expression: Modulation by environmental novelty. J Neurosci 18: 10579-10593.
5. Bannon MJ, Michaud RL, Roth RH. 1981. Mesocortical dopamine neurons. Lack of autoreceptors modulating dopamine synthesis. Mol Pharmacol 19: 270-275.
6. Bendotti C, Borsini F, Zanini MG, Samanin R, Garattini S. 1980. Effect of fenfluramine and norfenfluramine stereoisomers on stimulant effects of d-amphetamine and apomorphine in the rat. Pharmacol Res Commun 12: 567-574.
7. Best JA, Nijhout HF, Reed MC. 2009. Homeostatic mechanisms in dopamine synthesis and release: A mathematical model. Theor Biol Med Model 6: 21.
8. Blaschko H, Richter D, Schlossmann H. 1937. The oxidation of adrenaline and other amines. Biochem J 31: 2187-2196.
9. 3H]GBR 12783 binding to a specific site associated with the neuronal dopamine uptake complex in the central nervous system. Eur J Pharmacol 126: 211-222.
10. Braestrup C, Scheelkruger J. 1976. Methylphenidate-like effects of new antidepressant drug nomifensine (HOE 984). Eur J Pharmacol 38: 305-312.
11. Bunney BS, Aghajanian GK, Roth RH. 1973a. Comparison of effects of L-DOPA, amphetamine and apomorphine on firing rate of rat dopaminergic neurons. Nat New Biol 245: 123-125.
12. Bunney BS, Walters JR, Roth RH, Aghajanian GK. 1973b. Dopaminergic neurons: Effect of antipsychotic drugs and amphetamine on single cell activity. J Pharmacol Exp Ther 185: 560-571.
13. Butcher SP, Fairbrother IS, Kelly JS, Arbuthnott GW. 1990. Effects of selective monoamine-oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum. J Neurochem 55: 981-988.
14. Carboni E, Imperato A, Perezzani L, Dichiara G. 1989. Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats. Neuroscience 28: 653-661.
15. 125I]RTI-121 to filters: Effect of ions and cocaine. J Neurosci Meth 75: 179-186.
16. Cho AK, Melega WP, Kuczenski R, Segal DS, Schmitz DA. 1999. Caudate-putamen dopamine and stereotypy response profiles after intravenous and subcutaneous amphetamine. Synapse 31: 125-133.
17. Clausing P, Bloom D, Newport GD, Holson RR, Slikker W, Bowyer JF. 1996. Individual differences in dopamine release but not rotational behavior correlate with extracellular amphetamine levels in caudate putamen in unlesioned rats. Psychopharmacology 127: 187-194.
18. Clausing P, Bowyer JF. 1999. Time course of brain temperature and caudate/putamen microdialysate levels of amphetamine and dopamine in rats after multiple doses of d-amphetamine. In: Trembly BSW, editor. Neuroprotective agents: Fourth international conference. p 495-504.
19. Colzi A, Dagostini F, Cesura AM, Borroni E, Daprada M. 1993. Monoamine oxidase-A inhibitors and dopamine metabolism in rat caudatus-Evidence that an increased cytosolic level of dopamine displaces reversible monoamine oxidase-A inhibitors in vivo. J Pharmacol Exp Ther 265: 103-111.
20. Danielson TJ, Petrali EH, Wishart TB. 1976. Effect of acute and chronic injections of d-amphetamine sulfate and substantia nigra lesions on distribution of amphetamine and para-hydroxyamphetamine in rat-brain. Life Sci 19: 1265-1270.
21. 125I]iodoketanserin. Neuroscience 33: 341-349.
22. de la Fuente-Fernandez R, Schulzer M, Mak E, Calne DB, Stoessl AJ. 2004. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: A probabilistic model. Brain 127: 888-899.
23. Demarest KT, Lawson-Wendling KL, Moore KE. 1983. D-amphetamine and gamma-butyrolactone alteration of dopamine synthesis in the terminals of nigrostriatal and mesolimbic neurons. Possible role of various autoreceptor sensitivities. Biochem Pharmacol 32: 691-697.
24. Demarest KT, Moore KE. 1979. Comparison of dopamine synthesis regulation in the terminals of nigrostriatal, mesolimbic, tuberoinfundibular and tuberohypophyseal neurons. J Neural Transm 46: 263-277.
25. Demarest KT, Moore KE. 1981. Type-A monoamine-oxidase catalyzes the intra-neuronal deamination of dopamine within nigrostriatal, mesolimbic, tuberoinfundibular and tuberohypophyseal neurons in the rat. J Neural Transm 52: 175-187.
26. Doucet G, Descarries L, Garcia S. 1986. Quantification of the dopamine innervation in adult-rat neostriatum. Neuroscience 19: 427-445.
27. 3H]nomifensine to striatal membranes. Biochem Pharmacol 34: 1137-1144.
28. Dunkley PR, Bobrovskaya L, Graham ME, von Nagy-Felsobuki EI, Dickson PW. 2004. Tyrosine hydroxylase phosphorylation: Regulation and consequences. J Neurochem 91: 1025-1043.
29. Elverfors A, Nissbrandt H. 1992. Effects of d-amphetamine on dopaminergic neurotransmission-A comparison between the substantia-nigra and the striatum. Neuropharmacol 31: 661-670.
30. Finberg JPM, Wang J, Goldstein DS, Kopin IJ, Bankiewicz KS. 1995. Influence of selective-inhibition of monoamine-oxidase-A or monoamine-oxidase-B on striatal metabolism of L-DOPA in hemiparkinsonian rats. J Neurochem 65: 1213-1220.
31. Fleckenstein AE, Metzger RR, Wilkins DG, Gibb JW, Hanson GR. 1997. Rapid and reversible effects of methamphetamine on dopamine transporters. J Pharmacol Exp Ther 282: 834-838.
32. Fowler CJ, Benedetti MS. 1983. The metabolism of dopamine by both forms of monoamine-oxidase in the rat-brain and its inhibition by cimoxatone. J Neurochem 40: 1534-1541.
33. Fuller RW. 1968. Influence of substrate in inhibition of rat liver and brain monoamine oxidase. Arch Int Pharmacodyn Ther 174: 32-36.
34. Fuller RW, Hines CW. 1967. D-amphetamine levels in brain and other tissues of isolated and aggregated mice. Biochem Pharmacol 16: 11-16.
35. Fuller RW, Snoddy HD, Molloy BB. 1973. Effect of some lipid-soluble derivatives of amphetamine on amphetamine levels in rat-brain. J Pharm Pharmac 25: 828-829.
36. Garris PA, Wightman RM. 1994. Different kinetics govern dopaminergic transmission in the amygdala, prefrontal cortex, and striatum: An in vivo voltammetric study. J Neurosci 14: 442-450.
37. Green AL. 1971. Inhibition of rat and mouse brain monoamine oxidases by (+)-amphetamine. Biochem J 121: P37-P38.
38. Green AL, Elhait MAS. 1980. Para-methoxyamphetamine, a potent reversible inhibitor of type-A monoamine-oxidase in vitro and in vivo. J Pharm Pharmac 32: 262-266.
39. Gu H, Wall SC, Rudnick G. 1994. Stable expression of biogenic-amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. J Biol Chem 269: 7124-7130.
40. Guan XM, McBride WJ. 1988. Amphetamine-induced in vivo release of dopamine in the striatum is influenced by local pH. Life Sci 42: 2625-2631.
41. 3H]-catecholamines by homogenates of rat corpus striatum and cerebral-cortex-Effects of amphetamine analogs. Neuropharmacol 12: 669-679.
42. Heeringa MJ, Abercrombie ED. 1995. Biochemistry of somatodendritic dopamine release in substantia-nigra-An in-vivo comparison with striatal dopamine release. J Neurochem 65: 192-200.
43. Henderson MG, Fuller RW. 1992. Comparative brain levels of phenylpropanolamine and amphetamine in rats. Res Commun Chem Pathol Pharmacol 75: 247-250.
44. Horn AS. 1990. Dopamine uptake: A review of progress in the last decade. Prog Neurobiol 34: 387-400.
45. Hyde JF, Jerussi TP. 1983. Intersex difference in striatal amphetamine concentration is independent of age. Brain Res Bull 11: 127-128.
46. 3H]GBR-12935 binding in brain: A radioligand for selective labelling of the dopamine transport complex. J Neurochem 46: 1272-1276.
47. Janowsky A, Mah C, Johnson RA, Cunningham CL, Phillips TJ, Crabbe JC, Eshleman AJ, Belknap JK. 2001. Mapping genes that regulate density of dopamine transporters and correlated behaviors in recombinant inbred mice. J Pharmacol Exp Ther 298: 634-643.
48. Jones SR, Gainetdinov RR, Jaber M, Giros B, Wightman RM, Caron MG. 1998. Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc Natl Acad Sci USA 95: 4029-4034.
49. Jones SR, Joseph JD, Barak LS, Caron MG, Wightman RM. 1999. Dopamine neuronal transport kinetics and effects of amphetamine. J Neurochem 73: 2406-2414.
50. Jori A, Caccia S. 1974. Distribution of amphetamine and its hydroxylated metabolites in various areas of rat-brain. J Pharm Pharmac 26: 746-748.
51. Justice JB, C. NL, Michael AC. 1988. Modeling the dopaminergic nerve terminal. J Neurosci Meth 22: 239-252.
52. Kamata K, Rebec GV. 1983. Dopaminergic and neostriatal neurons-dose-dependent changes in sensitivity to amphetamine following long-term treatment. Neuropharmacol 22: 1377-1382.
53. Kaushik P, Gorin F, Vali S. 2007. Dynamics of tyrosine hydroxylase mediated regulation of dopamine synthesis. J Comp Neurosci 22: 147-160.
54. Kazahaya Y, Akimoto K, Otsuki S. 1989. Subchronic methamphetamine treatment enhances methamphetamine-induced or cocaine-induced dopamine efflux in vivo. Biol Psych 25: 903-912.
55. Kehr W, Speckenbach W, Zimmermann R. 1977. Interaction of haloperidol and gamma-butyrolactone with (+)-amphetamine-induced changes in monoamine synthesis and metabolism in rat-brain. J Neural Transm 40: 129-147.
56. Khoshbouei H, Sen N, Guptaroy B, Johnson L, Lund D, Gnegy ME, Galli A, Javitch JA. 2004. N-terminal phosphorylation of the dopamine transporter is required for amphetamine-induced efflux. PLoS Biol 2: 387-393.
57. Kilbourn M, Frey K. 1996. Striatal concentrations of vesicular monoamine transporters are identical in MPTP-sensitive (C57BL/6) and -insensitive (CD-1) mouse strains. Eur J Pharmacol 307: 227-232.
58. Kilts CD, Anderson CM, Ely TD, Nishita JK. 1987. Absence of synthesis-modulating nerve-terminal autoreceptors on mesoamygdaloid and other mesolimbic dopamine neuronal populations. J Neurosci 7: 3961-3975.
59. Kuczenski R. 1977. Biphasic effects of amphetamine on striatal dopamine dynamics. Eur J Pharmacol 46: 249-257.
60. Kuczenski R. 1980. Amphetamine-haloperidol interactions on striatal and mesolimbic tyrosine-hydroxylase activity and dopamine metabolism. J Pharmacol Exp Ther 215: 135-142.
61. Kuczenski R. 1983. Biochemical actions of amphetamine and other stimulants. In: Creese I, editor. Stimulants: neurochemical, behavioral, and clinical perspectives. New York: Raven Press. p 31-61.
62. Kuczenski R, Melega WP, Cho AK, Segal DS. 1997. Extracellular dopamine and amphetamine after systemic amphetamine administration: Comparison to the behavioral response. J Pharmacol Exp Ther 282: 591-596.
63. Kuczenski R, Segal D. 1989. Concomitant characterization of behavioral and striatal neurotransmitter response to amphetamine using in vivo microdialysis. J Neurosci 9: 2051-2065.
64. Kuczenski R, Segal DS. 1992. Differential-effects of amphetamine and dopamine uptake blockers (cocaine, nomifensine) on caudate and accumbens dialysate dopamine and 3-methoxytyramine. J Pharmacol Exp Ther 262: 1085-1094.
65. Kuczenski R, Segal DS, Aizenstein ML. 1991. Amphetamine, cocaine, and fencamfamine-relationship between locomotor and stereotypy response profiles and caudate and accumbens-dopamine dynamics. J Neurosci 11: 2703-2712.
66. Kuhn CM, Schanberg SM. 1978. Metabolism of amphetamine after acute and chronic administration to rat. J Pharmacol Exp Ther 207: 544-554.
67. Kuhr WG, Ewing AG, Near JA, Wightman RM. 1985. Amphetamine attenuates the stimulated release of dopamine in vivo. J Pharmacol Exp Ther 232: 388-394.
68. Levy A, Stillman MJ, Rauch TM. 1991. Cyclo (his-pro), d-amphetamine and striatal dopamine-A microdialysis study. Brain Res Bull 27: 129-131.
69. 3H]dopamine from isolated corpus striatum by amphetamine, fenfluramine and unlabeled dopamine. Biochem Pharmacol 31: 983-992.
70. Liljequist S, Engel J. 1979. Attenuation of the gamma-butyrolactone-induced increase in DOPA accumulation by chronic ethanol administration. J Neural Transm 46: 195-204.
71. Lindgren N, Usiello A, Goiny M, Haycock J, Erbs E, Greengard P, Hokfelt T, Borrelli E, Fisone G. 2003. Distinct roles of dopamine D2l and D2s receptor isoforms in the regulation of protein phosphorylation at presynaptic and postsynaptic sites. Proc Natl Acad Sci USA 100: 4305-4309.
72. Lindgren N, Xu ZQD, Herrera-Marschitz M, Haycock J, Hokfelt T, Fisone G. 2001. Dopamine D-2 receptors regulate tyrosine hydroxylase activity and phosphorylation at ser40 in rat striatum. Eur J Neurosci 13: 773-780.
73. Mantle TJ, Tipton KF, Garret NJ. 1976. Inhibition of monoamine oxidase by amphetamine and related compounds. Biochem Pharmacol 25: 2073-2077.
74. Melega WP, Williams AE, Schmitz DA, Distefano EW, Cho AK. 1995. Pharmacokinetic and pharmacodynamic analysis of the actions of d-amphetamine and d-methamphetamine on the dopamine terminal. J Pharmacol Exp Ther 274: 90-96.
75. Nagatsu T, Levitt M, Udenfriend S. 1964. Tyrosine hydroxylase: The initial step in norepinephrine biosynthesis. J Biol Chem 239: 2910-2917.
76. Nash JF, Yamamoto BK. 1993. Effect of d-amphetamine on the extracellular concentrations of glutamate and dopamine in iprindole-treated rats. Brain Res 627: 1-8.
77. Nicholson C. 1995. Interaction between diffusion and Michaelis-Menten uptake of dopamine after iontophoresis in striatum. Biophys J 68: 1699-1715.
78. O'Carroll AM, Fowler CJ, Phillips JP, Tobbia I, Tipton KF. 1983. The deamination of dopamine by human-brain monoamine-oxidase-Specificity for the 2 enzyme forms in 7 brain-regions. Naunyn-Schmiedeberg's Arch Pharmacol 322: 198-202.
79. Okuda C, Segal DS, Kuczenski R. 1992. Deprenyl alters behavior and caudate dopamine through an amphetamine-like action. Pharmacol Biochem Behav 43: 1075-1080.
80. Pani L, Gessa GL, Carboni S, Portas CM, Rossetti ZL. 1990. Brain dialysis and dopamine-Does the extracellular concentration of dopamine reflect synaptic release. Eur J Pharmacol 180: 85-90.
81. Partilla JS, Dempsey AG, Nagpal AS, Blough BE, Baumann MH, Rothman RB. 2006. Interaction of amphetamines and related compounds at the vesicular monoamine transporter. J Pharmacol Exp Ther 319: 237-246.
82. Patrick SL, Thompson TL, Walker JM, Patrick RL. 1991. Concomitant sensitization of amphetamine-induced behavioral stimulation and in vivo dopamine release from rat caudate-nucleus. Brain Res 538: 343-346.
83. Pearl RG, Seiden LS. 1979. D-amphetamine-induced increase in catecholamine synthesis in the corpus striatum of the rat-Persistence of the effect after tolerance. J Neural Transm 44: 21-38.
84. Philippu A, Beyer J. 1973. Dopamine and noradrenaline transport into subcellular vesicles of the striatum. Naunyn-Schmiedeberg's Arch Pharmacol 278: 387-402.
85. Pifl C, Singer EA. 1999. Ion dependence of carrier-mediated release in dopamine or norepinephrine transporter-transfected cells questions the hypothesis of facilitated exchange diffusion. Mol Pharmacol 56: 1047-1054.
86. Porenta G, Riederer P. 1982. A mathematical-model of the dopaminergic synapse-stability and sensitivity analyses, and simulation of Parkinson's disease and aging processes. Cybern Syst 13: 257-274.
87. Qi Z, Kikuchi S, Tretter F, Voit EO. 2011. Effects of dopamine and glutamate on synaptic plasticity: A computational modeling approach for drug abuse as comorbidity in mood disorders. Pharmacopsychiatry 44: S62-S75.
88. Qi Z, Miller GW, Voit EO. 2008a. Computational systems analysis of dopamine metabolism. PLoS One 3(6).
89. Qi Z, Miller GW, Voit EO. 2008b. A mathematical model of presynaptic dopamine homeostasis: Implications for schizophrenia. Pharmacopsychiatry 41: S89-S98.
90. Qi Z, Miller GW, Voit EO. 2010. Computational modeling of synaptic neurotransmission as a tool for assessing dopamine hypotheses of schizophrenia. Pharmacopsychiatry 43: S50-S60.
91. Raiteri M, Cerrito F, Cervoni AM, Levi G. 1979. Dopamine can be released by two mechanisms differentially affected by the dopamine transport inhibitor nomifensine. J Pharmacol Exp Ther 208: 195-202.
92. Ramsay RR, Hunter DJB. 2003. Interactions of d-amphetamine with the active site of monoamine oxidase-A. Inflammopharmacology 11: 127-133.
93. Rehavi M, Goldin M, Roz N, Weizman A. 1998. Regulation of rat brain vesicular monoamine transporter by chronic treatment with ovarian hormones. Mol Brain Res 57: 31-37.
94. Rice ME, Nicholson C. 1991. Diffusion characteristics and extracellular volume fraction during normoxia and hypoxia in slices of rat neostriatum. J Neurophys 65: 264-272.
95. Riviere GJ, Gentry WB, Owens SM. 2000. Disposition of methamphetamine and its metabolite amphetamine in brain and other tissues in rats after intravenous administration. J Pharmacol Exp Ther 292: 1042-1047.
96. Roth RH, Murrin LC, Walters JR. 1976. Central dopaminergic-neurons-effects of alterations in impulse flow on accumulation of dihydroxyphenylacetic acid. Eur J Pharmacol 36: 163-171.
97. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS. 2001. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39: 32-41.
98. 125I] RTI-55. J Pharmacol Exp Ther 270: 296-309.
99. Rutledge CO. 1970. Mechanisms by which amphetamine inhibits oxidative deamination of norepinephrine in brain. J Pharmacol Exp Ther 171: 188-195.
100. Salama AI, Goldberg ME. 1969. Effect of several models of stress and amphetamine on brain levels of amphetamine and certain monoamines. Arch Int Pharmacodyn Ther 181: 474-483.
101. Scherman D. 1986. Dihydrotetrabenazine binding and monoamine uptake in mouse- brain regions. J Neurochem 47: 331-339.
102. Scherman D, Boschi G. 1988. Time required for transmitter accumulation inside monoaminergic storage-vesicles differs in peripheral and in central systems. Neuroscience 27: 1029-1035.
103. 3H] dihydrotetrabenazine binding-sites in the mouse-brain and its relationship to the distribution of monoamines and their metabolites. Brain Res 370: 176-181.
104. 3H]dihydrotetrabenazine, a new in vitro monoaminergic probe for human-brain. J Neurochem 50: 1131-1136.
105. Schoepp DD, Azzaro AJ. 1981. Specificity of endogenous substrates for type-A and type-B monoamine-oxidase in rat striatum. J Neurochem 36: 2025-2031.
106. Scorza MC, Carrau C, Silveira R, ZapataTorres G, Cassels BK, ReyesParada M. 1997. Monoamine oxidase inhibitory properties of some methoxylated and alkylthio amphetamine derivatives-structure-activity relationships. Biochem Pharmacol 54: 1361-1369.
107. Segal DS, Kuczenski R, Okuda C. 1992. Clorgyline-induced increases in presynaptic DA-Changes in the behavioral and neurochemical effects of amphetamine using in vivo microdialysis. Pharmacol Biochem Behav 42: 421-429.
108. Sharp T, Zetterstrom T, Ljungberg T, Ungerstedt U. 1986. Effect of sulpiride on amphetamine-induced behavior in relation to changes in striatal dopamine release in vivo. Eur J Pharmacol 129: 411-415.
109. Sharp T, Zetterstrom T, Ljungberg T, Ungerstedt U. 1987. A direct comparison of amphetamine-induced behaviors and regional brain dopamine release in the rat using intracerebral dialysis. Brain Res 401: 322-330.
110. Silva MAD, Mattern C, Hacker R, Nogueira PJC, Huston JP, Schwarting RKW. 1997. Intranasal administration of the dopaminergic agonists L-DOPA, amphetamine, and cocaine increases dopamine activity in the neostriatum: A microdialysis study in the rat. J Neurochem 68: 233-239.
111. Sitte HH, Freissmuth M. 2010. The reverse operation of Na(+)/Cl(-)-coupled neurotransmitter transporters-Why amphetamines take two to tango. J Neurochem 112: 340-355.
112. Sitte HH, Huck S, Reither H, Boehm S, Singer EA, Pifl C. 1998. Carrier-mediated release, transport rates, and charge transfer induced by amphetamine, tyramine, and dopamine in mammalian cells transfected with the human dopamine transporter. J Neurochem 71: 1289-1297.
113. 3-dopamine uptake into rat brain homogenates. J Pharmacol Exp Ther 165: 78-86.
114. Sood P, Cole S, Fraier D, Young AMJ. 2009. Evaluation of metaquant microdialysis for measurement of absolute concentrations of amphetamine and dopamine in brain: A viable method for assessing pharmacokinetic profile of drugs in the brain. J Neurosci Meth 185: 39-44.
115. Sulzer D, Chen TK, Lau YY, Kristensen H, Rayport S, Ewing A. 1995. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci 15: 4102-4108.
116. Sulzer D, Sonders MS, Poulsen NW, Galli A. 2005. Mechanisms of neurotransmitter release by amphetamines: A review. Prog Neurobiol 75: 406-433.
117. Takahashi N, Miner LL, Sora I, Ujike H, Revay RS, Kostic V, Jackson-Lewis V, Przedborski S, Uhl GR. 1997. VMAT2 knockout mice: Heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc Natl Acad Sci, USA 94: 9938-9943.
118. Tognoni G, Morselli PL, Garattin .S. 1972. Amphetamine concentrations in rat-brain and human urine after fenproporex administration. Eur J Pharmacol 20: 125-126.
119. Tretter F, Ebberle E, Scherer J. 2002. A basic mathematical model of a dopamine synapse. Cyber Syst 2002 1: 335-339.
120. Venton BJ, Zhang H, Garris PA, Phillips PEM, Sulzer D, Wightman RM. 2003. Real-time decoding of dopamine concentration changes in the caudate-putamen during tonic and phasic firing. J Neurochem 87: 1284-1295.
121. Wallace LJ. 2007. A small dopamine permeability of storage vesicle membranes and end product inhibition of tyrosine hydroxylase are sufficient to explain changes occurring in dopamine synthesis and storage after inhibition of neuron firing. Synapse 61: 715-723.
122. Wallace LJ. 2010. Striatal dopamine storage and utilization. In: Farooqui T, Farooqui AA, editors. Biogenic amines-Pharmacological, neurochemical and molecular aspects in the CNS. New York: Nova Biomedical Books. p 47-69.
123. Wallace LJ, Connell LE. 2008. Mechanisms by which amphetamine redistributes dopamine out of vesicles: A computational study. Synapse 62: 370-378.
124. Wallace LJ, Hughes RM. 2008. Computational analysis of stimulated dopaminergic synapses suggests release largely occurs from a single pool of vesicles. Synapse 62: 909-919.
125. Wallace LJ, Traeger JS. 2012. DOPAC distribution and regulation in striatal dopaminergic varicosities and extracellular space. Synapse 66: 160-173.
126. Walters JR, Roth RH. 1974. Dopaminergic neurons: Drug-induced antagonism of the increase in tyrosine hydroxylase activity produced by cessation of impulse flow. J Pharmacol Exp Ther 191: 82-91.
127. Westerink BHC, Vanputten FMS. 1987. Simultaneous determination of the rates of synthesis and metabolism of dopamine in various areas of the rat-brain-Application to the effects of (+)-amphetamine. Eur J Pharmacol 133: 103-110.
128. White FJ, Wang RY. 1984. Electrophysiological evidence for A10 dopamine autoreceptor subsensitivity following chronic d-amphetamine treatment. Brain Res 309: 283-292.
129. Wightman RM, Amatore C, Engstrom RC, Hale PD, Kristensen EW, Kuhr WG, May LJ. 1988. Real-time characterization of dopamine overflow and uptake in the rat striatum. Neuroscience 25: 513-523.
130. 3H] amphetamine with rat-brain synaptosomes. 2. Active-transport. J Pharmacol Exp Ther 257: 830-835.
131. Zetterstrom T, Sharp T, Marsden CA, Ungerstedt U. 1983. In vivo measurement of dopamine and its metabolites by intracerebral dialysis-Changes after d-amphetamine. J Neurochem 41: 1769-1773.
132. Zirkle CL, Kaiser C. 1964. Monoamine oxidase inhibitors (nonhydrazines). In: Gordon M, editor. Psychopharmacological agents. New York: Academic Press Inc. p 474-475.